CN109689053A - 局部雷帕霉素疗法 - Google Patents

局部雷帕霉素疗法 Download PDF

Info

Publication number
CN109689053A
CN109689053A CN201780049324.6A CN201780049324A CN109689053A CN 109689053 A CN109689053 A CN 109689053A CN 201780049324 A CN201780049324 A CN 201780049324A CN 109689053 A CN109689053 A CN 109689053A
Authority
CN
China
Prior art keywords
composition
rapamycin
patient
weight
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780049324.6A
Other languages
English (en)
Chinese (zh)
Inventor
玛丽·卡伊·凯尼格
霍普·诺思拉普
阿德莱德·A·赫伯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN109689053A publication Critical patent/CN109689053A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780049324.6A 2016-08-10 2017-08-10 局部雷帕霉素疗法 Pending CN109689053A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662372940P 2016-08-10 2016-08-10
US62/372,940 2016-08-10
PCT/US2017/046320 WO2018031789A1 (en) 2016-08-10 2017-08-10 Topical rapamycin therapy

Publications (1)

Publication Number Publication Date
CN109689053A true CN109689053A (zh) 2019-04-26

Family

ID=59684091

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049324.6A Pending CN109689053A (zh) 2016-08-10 2017-08-10 局部雷帕霉素疗法

Country Status (11)

Country Link
US (1) US20190167649A1 (https=)
EP (1) EP3496712A1 (https=)
JP (1) JP2019527711A (https=)
KR (1) KR20190039220A (https=)
CN (1) CN109689053A (https=)
AU (1) AU2017311491A1 (https=)
BR (1) BR112019002689A2 (https=)
CA (1) CA3032473A1 (https=)
MX (1) MX2019001670A (https=)
RU (1) RU2019106483A (https=)
WO (1) WO2018031789A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109431997A (zh) * 2018-12-20 2019-03-08 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
WO2019156999A1 (en) * 2018-02-06 2019-08-15 Georgetown University TOPICAL mTOR INHIBITORS FOR CUTANEOUS PROLIFERATIVE AND VASCULAR CONDITIONS
US11000513B2 (en) 2018-07-02 2021-05-11 Palvella Therapeutics, Inc. Anhydrous compositions of mTOR inhibitors and methods of use
WO2020047342A1 (en) * 2018-08-30 2020-03-05 Chemistryrx Sirolimus containing compositions
BR112021016296A2 (pt) 2019-02-20 2021-11-09 Ai Therapeutics Inc Formulações tópicas de rapamicina e seu uso em tratamento de angiofibromas faciais e outros distúrbios de pele
US20220142990A1 (en) * 2019-02-27 2022-05-12 Osaka University External preparation for treating a vascular anomaly
US20230056335A1 (en) 2020-01-24 2023-02-23 Nobelpharma Co., Ltd. Topical formulation containing rapamycin
AU2020277132B1 (en) * 2020-11-24 2021-11-04 Aft Pharmaceuticals Limited A Rapamycin Composition
AU2023203871B1 (en) * 2023-06-20 2024-07-25 Aft Pharmaceuticals Ltd A Rapamycin Method of Treatment and Composition

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315942A1 (en) * 2013-01-24 2014-10-23 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
GB9723669D0 (en) 1997-11-07 1998-01-07 Univ Aberdeen Skin penetration enhancing components
EP1546369A4 (en) 2002-08-12 2007-01-17 Univ Michigan DIAGNOSIS AND TREATMENT OF DISEASES THROUGH DEFECTS IN THE TUBEROUS SKLEROSEPFAD
JP2008531686A (ja) 2005-03-02 2008-08-14 ワイス ラパマイシンの精製
LT1983984T (lt) 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
US20120022095A1 (en) * 2010-06-24 2012-01-26 Teng Joyce M C Topical rapamycin for treatment of facial angiofibromas in tuberous sclerosis
US20130102572A1 (en) * 2011-04-12 2013-04-25 Dow Pharmaceutical Sciences Methods of treating skin conditions exhibiting telangiectasia
HUP1400075A2 (hu) * 2014-02-14 2015-08-28 Druggability Technologies Ip Holdco Jersey Ltd Sirolimus és származékainak komplexei, elõállítása és gyógyszerészeti kompozíciói
KR20180081501A (ko) * 2015-09-24 2018-07-16 드렉셀유니버시티 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법
CN105663027B (zh) * 2016-04-01 2018-12-18 中国人民解放军广州军区武汉总医院 西罗莫司外用制剂、其制备方法及用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140315942A1 (en) * 2013-01-24 2014-10-23 Transderm, Inc. COMPOSITIONS FOR TRANSDERMAL DELIVERY OF mTOR INHIBITORS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GUILLAUME BOUGUÉON 等: "Formulation and characterization of a 0.1% rapamycin cream for the treatment of Tuberous Sclerosis Complex-related angiofibromas", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 *
R. BALESTRI等: "Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in Tuberous Sclerosis Complex", 《JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY》 *
RAMONY CAJAL HOSPITAL MADRID: "Facial angiofibromas treated with topical rapamycin：An excellent choice with fast response", 《DERMATOLOGY ONLINE JOURNAL》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109431997A (zh) * 2018-12-20 2019-03-08 武汉科福新药有限责任公司 一种雷帕霉素局部注射制剂及其制备方法

Also Published As

Publication number Publication date
RU2019106483A (ru) 2020-09-11
AU2017311491A1 (en) 2019-02-07
WO2018031789A1 (en) 2018-02-15
JP2019527711A (ja) 2019-10-03
KR20190039220A (ko) 2019-04-10
BR112019002689A2 (pt) 2019-05-14
CA3032473A1 (en) 2018-02-15
EP3496712A1 (en) 2019-06-19
US20190167649A1 (en) 2019-06-06
RU2019106483A3 (https=) 2020-12-04
MX2019001670A (es) 2019-07-04

Similar Documents

Publication Publication Date Title
CN109689053A (zh) 局部雷帕霉素疗法
AU2002317053B2 (en) Dermal therapy using phosphate derivatives of electron transfer agents
US20250114497A1 (en) Skin composition
KR101450409B1 (ko) 선스크린 조성물
CN106852126A (zh) 用于递送皮肤护理用活性成分的透明组合物和方法
Chen et al. A novel topical nano-propranolol for treatment of infantile hemangiomas
JP2024023429A (ja) 皮膚状態の処置のための組成物
JP2017502053A (ja) 炎症性皮膚状態を治療するためのアラントイン組成物
US9034845B2 (en) Compositions for treating rosacea
Varvaresou et al. Targeted therapy in oncology patients and skin: Pharmaceutical and dermocosmetic management
US7022332B2 (en) Sulfacetamide formulations for treatment of rosacea
EP4210667B1 (en) Dermal compositions replicating the vernix caseosa
JPWO2007135841A1 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有化粧料
JP5225655B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有乳化組成物
CN115038427A (zh) 局部用孟鲁司特制剂
JP5225654B2 (ja) ダイマージリノール酸ジエチレングリコールオリゴマーエステル含有乳化組成物
US20250134805A1 (en) Enhanced mucous adhesion via a complex of carboxymethyl starch and pullulan polymers
EP4566589A1 (en) Pharmaceutical composition for prevention and alleviation of early skin reactions caused by irradiation in patients treated for cancer
US20060239944A1 (en) Sulfacetamide formulations for treatment of skin dermatoses
AU2014386711B2 (en) Compositions that assist skin healing and/or maintain skin health
JP2020100576A (ja) 皮膚外用組成物
Samadi et al. Comparison of Urea-Based Compounding Moisturizers and Similar Commercial Products on Skin Barrier Function: A Randomized Biometric Study.
JP7282476B2 (ja) 外用組成物
KR20240007076A (ko) 페길화된 빌리루빈을 포함하는 염증성 질환의 예방또는 치료용 약학 조성물
HK40078592A (en) Topical montelukast formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190426

WD01 Invention patent application deemed withdrawn after publication